Skip to main content
. 2017 May 11;8(26):43153–43168. doi: 10.18632/oncotarget.17820

Figure 1. Specific knockdown of IL-17RC expression in B16 melanoma cells attenuates tumor growth in vitro and in vivo.

Figure 1

B16 cells were transduced with retroviral vectors containing shRNAs against IL-17RC or random sequences. IL-17RC expression by different knockdown sub-clones was determined by qRT-PCR and RT-PCR (a) and flow cytometry (b). The threshold of gene expression for selecting the best knockdown is shown as a red line. (c) CXCL1 production upon IL-17A and IL-17F stimulation was determined by ELISA. (d-f) Cell growth was measured by direct cell counting and MTT assay with or without serum-free starvation treatment and correlation analysis with IL-17RC expression. (g) Tumor weight and volume of B16-IL-17RCKD and B16-pSMP control cells in C57BL/6 mice was determined. All values are presented as the mean ± SEM of 3 independent experiments for in vitro studies (a-f), or the mean ± SEM of 5-15 mice per group per time point for in vivo studies (g). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; statistical analysis was compared with the pSMP control.